WBH Advisory Inc. Sells 303 Shares of Eli Lilly and Company (NYSE:LLY)

WBH Advisory Inc. lessened its stake in Eli Lilly and Company (NYSE:LLY) by 2.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,493 shares of the company’s stock after selling 303 shares during the period. WBH Advisory Inc.’s holdings in Eli Lilly and Company were worth $5,390,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Silicon Valley Capital Partners acquired a new position in shares of Eli Lilly and Company in the 1st quarter worth approximately $25,000. Bogart Wealth LLC grew its position in Eli Lilly and Company by 193.3% in the first quarter. Bogart Wealth LLC now owns 88 shares of the company’s stock valued at $30,000 after acquiring an additional 58 shares during the period. Laffer Tengler Investments acquired a new position in Eli Lilly and Company during the first quarter worth $33,000. Raleigh Capital Management Inc. boosted its stake in shares of Eli Lilly and Company by 156.4% in the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock valued at $34,000 after purchasing an additional 61 shares in the last quarter. Finally, Tanglewood Legacy Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $37,000. Institutional investors own 81.38% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 107,022 shares of the stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $459.28, for a total transaction of $49,153,064.16. Following the completion of the sale, the insider now owns 101,248,810 shares of the company’s stock, valued at $46,501,553,456.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, major shareholder Lilly Endowment Inc sold 107,022 shares of the company’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $459.28, for a total transaction of $49,153,064.16. Following the completion of the transaction, the insider now directly owns 101,248,810 shares of the company’s stock, valued at $46,501,553,456.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Alonzo Weems sold 1,148 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $590.98, for a total value of $678,445.04. Following the completion of the sale, the executive vice president now directly owns 7,760 shares in the company, valued at approximately $4,586,004.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 976,153 shares of company stock valued at $21,080,192,113. 0.13% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of Eli Lilly and Company from $500.00 to $615.00 and gave the company an “overweight” rating in a research report on Tuesday, August 8th. JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $510.00 to $600.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 9th. Jefferies Financial Group upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price objective for the company from $408.00 to $615.00 in a research report on Tuesday, August 8th. Truist Financial boosted their price objective on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Argus increased their price objective on Eli Lilly and Company from $470.00 to $620.00 and gave the company a “buy” rating in a research report on Tuesday, September 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and twenty have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $532.78.

Eli Lilly and Company Trading Up 0.5 %

Shares of LLY stock traded up $2.69 on Tuesday, hitting $573.97. The stock had a trading volume of 730,063 shares, compared to its average volume of 3,024,253. The company has a current ratio of 1.13, a quick ratio of 0.87 and a debt-to-equity ratio of 1.63. Eli Lilly and Company has a twelve month low of $296.32 and a twelve month high of $601.84. The company has a fifty day moving average price of $512.56 and a two-hundred day moving average price of $439.28. The firm has a market cap of $544.86 billion, a P/E ratio of 80.02, a PEG ratio of 2.37 and a beta of 0.32.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Tuesday, August 8th. The company reported $2.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. The firm had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The company’s revenue was up 28.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.25 earnings per share. As a group, analysts forecast that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were issued a dividend of $1.13 per share. The ex-dividend date was Monday, August 14th. This represents a $4.52 annualized dividend and a yield of 0.79%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 62.87%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.